Laboratorios Farmaceuticos Rovi Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Laboratorios Farmaceuticos Rovi heeft een totaal eigen vermogen van €558.2M en een totale schuld van €112.2M, wat de schuld-eigenvermogensverhouding op 20.1% brengt. De totale activa en totale passiva bedragen respectievelijk €877.8M en €319.7M. De EBIT Laboratorios Farmaceuticos Rovi is €212.6M waardoor de rentedekking 69.7 is. Het heeft contanten en kortetermijnbeleggingen van €17.6M.
Belangrijke informatie
20.1%
Verhouding schuld/eigen vermogen
€112.19m
Schuld
| Rente dekkingsratio | 69.7x |
| Contant | €17.55m |
| Aandelen | €558.19m |
| Totaal verplichtingen | €319.66m |
| Totaal activa | €877.85m |
Recente financiële gezondheidsupdates
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Aug 29
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22Recent updates
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 10With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
Oct 21Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Aug 29Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Jul 15We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Jun 17Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
May 08These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( €553.8M ) ROVI } overtreffen de korte termijn passiva ( €221.5M ).
Langlopende schulden: De kortetermijnactiva ROVI ( €553.8M ) overtreffen de langetermijnschulden ( €98.2M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 17% ) ROVI wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van ROVI is de afgelopen 5 jaar gestegen van 7.2% naar 20.1%.
Schuldendekking: De schuld van ROVI wordt goed gedekt door de operationele kasstroom ( 112.5% ).
Rentedekking: De rentebetalingen op de schuld van ROVI worden goed gedekt door EBIT ( 69.7 x dekking).